Updates are available Correction dated 2025-10-28
Click to view Correction: https://doi.org/10.1038/s41388-025-03614-7
-
Authors
Cherif, Chaïma https://orcid.org/0000-0002-5689-0327
Nguyen, Dang Tan
Paris, Clément
Le, Thi Khanh
Sefiane, Thibaud
Carbuccia, Nadine
Finetti, Pascal https://orcid.org/0000-0002-2674-3123
Chaffanet, Max https://orcid.org/0000-0002-2344-1488
kaoutari, Abdessamad El
Vernerey, Julien
Fazli, Ladan
Gleave, Martin
Manai, Mohamed
Barthélémy, Philippe https://orcid.org/0000-0003-3917-0579
Birnbaum, Daniel https://orcid.org/0000-0001-7920-9883
Bertucci, François
Taïeb, David
Rocchi, Palma https://orcid.org/0000-0002-4383-4684
- License Information
-
More Information
Article History
Received: 5 January 2021
Revised: 9 September 2021
Accepted: 27 September 2021
First Online: 28 October 2021
Change Date: 23 October 2025
Change Type: Update
Change Details: The original online version of this article was revised:
Change Details: In the original version, details about the animal ethics approval were not mentioned in the section ‘Assessment of in vivo tumor growth’. Accordingly the text passage now reads as follows:
Change Details: ‘P. Rocchi who supervised the animal experiments, obtained permission for animal experiments by ethical committee following European rules (APAFIS#26169-2020062314545490 v4, Direction générale de la recherche et de l'innovation (DGRI), 75231 Paris Cedex 05)’ instead of ‘Palma Rocchi possesses personal agreement (#A13-477) for the animal handling and experimentation for this study. Animal experimentation was carried out accordingly to ethics laws recommendations’.
Change Details: Correction to: Competing InterestsIn the original version, the ‘Competing Interest’ statement was incorrectly given as ‘The authors declare no competing interests’ but should have been ‘The University of British Columbia has submitted patent applications on Apatorsen, an antisense inhibitor of Hsp27, listing PR and MG as inventors. This IP has been licensed to OncoGenex Technologies, a Vancouver-based biotechnology company. P.R and D.T are cofounders of SilonTx ([Silon Therapeutics | Advancing Innovative Therapies|
Change Details: https://silontx.com/
Change Details: ]), a biotech company started in April 2024 focusing on precision medicine and nucleic acid therapeutics’.
Change Date: 28 October 2025
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41388-025-03614-7
Competing interests
: The University of British Columbia has submitted patent applications on Apatorsen, an antisense inhibitor of Hsp27, listing PR and MG as inventors. This IP has been licensed to OncoGenex Technologies, a Vancouver-based biotechnology company. P.R and D.T are cofounders of SilonTx ([Silon Therapeutics | Advancing Innovative Therapies| ]), a biotech company started in April 2024 focusing on precision medicine and nucleic acid therapeutics.
